Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

COVID-19 vaccination is effective in most cancer patients, but the level of protection against COVID-19 infection, hospitalisation and death offered by the vaccine is less than in the general population and vaccine effectiveness wanes more quickly.

Illustration of the Coronavirus © Gerd Altmann

A study co-led by the Universities of Oxford, Birmingham and Southampton and the UK Health Security Agency (UKHSA), published in Lancet Oncology today by the UK Coronavirus Cancer Evaluation Project, has found that while COVID-19 vaccination is effective in most cancer patients, the level of protection against COVID-19 infection, hospitalisation and death offered by the vaccine is less than in the general population and vaccine effectiveness wanes more quickly.

Dr Lennard Lee from the Department of Oncology, who led the study said: ‘We know that people with cancer have a higher risk of severe COVID-19 disease and that the immune response in cancer patients following COVID-19 vaccination is lower. However, no study has looked at vaccine effectiveness and its waning in cancer patients at a population level. We have undertaken the largest real-world health system evaluation of COVID-19 in cancer patients globally.’

This study analysed 377,194 individuals with active or recent cancer who had received two doses of the COVID-19 vaccine and undergone a SARS-CoV-2 PCR test in England1. The numbers of breakthrough COVID-19 infections and COVID-19-associated hospitalisations and deaths2 in this cohort of cancer patients were compared to a control population without active or recent cancer.

The overall vaccine effectiveness against COVID-19 infection in the general population after two doses of the COVID-19 vaccine over the study period was 69.8% whereas, in the cancer cohort, overall vaccine effectiveness was slightly lower (65.5%). This indicates that COVID-19 vaccination is effective in most cancer patients. However, vaccine effectiveness wanes more quickly in cancer patients. At 3-6 months following the second vaccine dose, vaccine effectiveness reduced by nearly a third from 61.4% in the general population to 47.0% in the cancer cohort.

While the vaccine offers higher protection against COVID-19-associated hospitalisation (83.3%) and death (93.4%) than against breakthrough infections in the cancer cohort, this protection also waned by 3-6 months following the second vaccine dose.

Looking at the differences between people with different types of cancer, vaccine effectiveness is lowest and wanes most quickly in those with the blood cancers lymphoma and leukaemia.

The type of treatment that people with cancer receive also impacts both overall vaccine effectiveness and waning. In cancer patients that were treated in the last 12 months with chemotherapy or radiotherapy, vaccine effectiveness is lower and waned more by 3–6 months than in cancer patients that did not receive these treatments or were treated more than a year ago.

Professor Peter Johnson, Professor of Medical Oncology, University of Southampton commented: ‘This study shows that for some people with cancer, COVID-19 vaccination may give less effective and shorter-lasting protection. This highlights the importance of vaccination booster programmes and rapid access to COVID-19 treatments for people undergoing cancer treatments.’

Helen Rowntree, Director of Research, Services and Engagement at Blood Cancer UK said: ‘For our community, COVID-19 very much has not gone away and many people remain in their homes due to the threat of COVID-19 highlighted in this important study. We know how important the vaccines are for people with blood cancer. This study importantly shows that immunity wanes faster in people with blood cancer, who are entitled to five vaccine doses, and we’d encourage everyone with blood cancer to make sure they are getting these doses.’

NOTES:

1This study analysed 377,194 individuals aged over 18 years with active or recent cancer (diagnosed between 1 January 2018 and 30 April 2021) who had received two doses of the COVID-19 vaccine and undergone a SARS-CoV-2 PCR test in England (between 8 December 2020 and 15 October 2021). The analysis controlled for clinically relevant covariates, including age, gender, deprivation index and ethnicity.

2Breakthrough infections were defined as a positive SARS-CoV-2 PCR test following the completion of the second vaccination dose. COVID-19 hospitalisation was defined as a hospitalisation episode from -1 to +14 days of a positive SARS-CoV-2 PCR test. COVID-19 death was a death up to 28 days following a positive SARS-CoV-2 PCR test.

Similar stories

Multi-cancer blood test shows real promise in NHS trial

An NHS trial of a new blood test for more than 50 types of cancer correctly revealed two out of every three cancers in more than 5,000 people who had visited their GP with suspected symptoms, in England or Wales. The test also correctly identified the original site of cancer in 85% of those cases.

The Howat Foundation to fund Chair in Clinical Oncology

Oxford Cancer announce the endowment of a Chair in Clinical Oncology, thanks to generous philanthropic support from The Howat Foundation

New Oxford and Nottingham developed tool uses existing health records to predict people’s risk of developing lung cancer within the next 10 years

A team of researchers from the University of Oxford and the University of Nottingham have developed a new tool, called ‘CanPredict’, aimed at identifying the people most at risk of developing lung cancer over the next 10 years, and put them forward for screening tests earlier, saving time, money and, most importantly, lives.

Scientists find genetic ‘marker’ linked to serious side-effects from skin cancer treatment

New research from the Fairfax Group has identified a genetic marker that could be used to predict a patient’s risk of developing serious side-effects when undergoing immunotherapy treatment for metastatic melanoma.

Oxford gets £122m funding for healthcare research

Health and care research in Oxford is to receive £122 million in government funding over the next five years to improve diagnosis, treatment and care for NHS patients. The funding was awarded to the city’s two National Institute for Health and Care Research (NIHR) Biomedical Research Centres (BRC).

The Department represented at the European Radiation Research Society annual conference

Researchers from the Department of Oncology attend the prestigious European Radiation Research Society (ERRS) in annual conference in Catania, Italy to present their research in Radiation Oncology.